Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

MYLAN INC
Mes dernières consult.
Most popular
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 11 990 M
EBIT 2017 3 266 M
Net income 2017 1 422 M
Debt 2017 13 558 M
Yield 2017 -
Sales 2018 12 471 M
EBIT 2018 3 645 M
Net income 2018 2 080 M
Debt 2018 11 385 M
Yield 2018 -
P/E ratio 2017 13,20
P/E ratio 2018 9,52
EV / Sales2017 2,50x
EV / Sales2018 2,23x
Capitalization 16 475 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted... 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
08/17 MYLAN : Finalizes Settlement Agreement on Medicaid Rebate Classification for Epi..
08/14 MYLAN NV : Today's Research Reports on Stocks to Watch: Adamis Pharmaceuticals a..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/10 MYLAN : Advances Access in the Fight Against HIV with the Launch of Three Generi..
08/10 MYLAN NV : Featured Company News - Mylan Launches Avonza(TM) in India
08/10DJMylan Cuts View On Drug Delays -- WSJ
08/09DJMylan Defers Product Launches -- 3rd Update
08/09DJMylan Defers Product Launches -- 2nd Update
More news
Sector news : Pharmaceuticals - NEC
08/18DJCorrection to Biogen Treads Tricky Path Between Politicians, Investors Articl..
08/18DJMERCK AND : Scientists, Out $12 Million, Sue Delaware Over Seizure of Their Stoc..
08/18DJASTRAZENECA : FDA Approves AstraZeneca's Ovarian Cancer Treatment Lynparza Table..
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/17 Drugmaker Hikma trims sales forecasts, shares fall
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 40,7 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC16 475
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705